First canine patient receives Vetigenics’ fully canine anti-CTLA4 monoclonal antibody for oral melanoma
Two fully funded pilot studies to treat cancer free for pet owners who bring their dogs to research sites. PHILADELPHIA, Nov. 2, 2023—Vetigenics, a clinical-stage biopharmaceutical company advancing antibody-based therapies for pets, announces that the first canine patient with stage 4 oral melanoma has received his first dose of Vetigenics’ fully canine anti-CTLA4 monoclonal antibody […]
Vetigenics’ Canibody platform attracting more potential collaborators
US pet therapeutics start-up Vetigenics is seeing increased interest from potential collaborators in its Canibody. Adriann Sax, the co-founder and chief executive of the Philadelphia-based company, recently revealed the company’s progress to S&P Global’s head of animal health Joseph Harvey. In late 2022, Vetigenics secured its second discovery partner for its companion animal therapeutic antibody […]
Enhancing Canine Wellness: The Promise of Immunotherapy for Dogs
Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find ways to improve canine health. One method that has been – and is still being – explored is the use of immunotherapy, which uses a dog’s own immune system to fight health issues, such as […]
Vetigenics Announces Second Discovery Collaboration with a Major Animal Health Pharma
New partnership established to explore multiple novel therapeutic antibodies for treating challenging pet diseases. Read More
Vetigenics Announces Publication of Comprehensive Preclinical Data for Anti-Canine CTLA4 Monoclonal Antibody
Published study confirms validity of the first entirely canine phage display technology to generate unique canine immunotherapy for treating canine cancer. Read More
Vetigenics Receives Startup of the Year Award from Penn Center for Innovation
Successful creation of the first entirely canine phage display platform for research and development of antibody immunotherapy spurs recognition for Vetigenics. Read More
Vetigenics Announces Discovery Collaboration With Merck Animal Health
Partnership extended to explore multiple novel therapeutic antibodies for treating challenging pet diseases PHILADELPHIA, Nov. 2, 2021 /PRNewswire/ — VETIGENICS, an animal health biotechnology company, today announced that it is extending its discovery collaboration with Merck Animal Health, a division of Merck & Co., Inc. for use of the VETIGENICS CANIBODY™ Platform to discover and […]
Animal Health Innovation USA | Virtual Event
Please join us on June 16 at 12:45pm to learn more about Vetigenics as a Innovation Showcase Finalist at the Animal Health Innovation USA virtual event.
Vetigenics Aims to Solve Challenges in Canine Immunotherapy Discovery and Development
Adriann Sax has been appointed to advance Vetigenics from an academic start-up to an independent animal health biotech company. Ms Sax was hired earlier this year as the firm’s chief executive. While her undergraduate education and early career focused on animal health, Ms Sax has spent the last several decades in the human biopharma sector […]
An Interview with Adriann Sax, Biotech Executive & Entrepreneur
This week, Jason Colodne, Managing Partner at Colbeck, spoke with Adriann Sax, co-founder and CEO at Vetigenics, a prominent innovator in animal health that is one of the first companies to produce antibody-based immunotherapies for canines. She formerly served as CEO of Orsenix, a clinical stage biotech company focused on developing novel therapies to treat […]